Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etodolac kinetics in the elderly.

J Scatina, D Hicks, M Kraml

    Clinical Pharmacology and Therapeutics
    |May 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A consensus statement on a National Competency Framework for training and assessment of knowledge and skills in diabetes technologies, including hybrid closed loop (HCL), insulin pump systems, and continuous glucose monitoring (CGM) devices.

    Diabetic medicine : a journal of the British Diabetic Association·2026
    Same author

    Search for Dark Matter Produced in Association with a Dark Higgs Boson in the bb[over ¯] Final State Using pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Search for Magnetic Monopole Pair Production in Ultraperipheral Pb+Pb Collisions at sqrt[s_{NN}]=5.36  TeV with the ATLAS Detector at the LHC.

    Physical review letters·2025
    Same author

    Simultaneous Unbinned Differential Cross-Section Measurement of Twenty-Four Z+jets Kinematic Observables with the ATLAS Detector.

    Physical review letters·2025
    Same author

    Disentangling Sources of Momentum Fluctuations in Xe+Xe and Pb+Pb Collisions with the ATLAS Detector.

    Physical review letters·2025
    Same author

    The effects of surface heterogeneity on erosion and sedimentation and their implications for of soil properties at postmining sites.

    The Science of the total environment·2024
    Same journal

    Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Clinical Characterization of Enzyme and Transporter Precipitants to Evaluate Drug-Drug Interactions for Orforglipron, a Small Molecule Glucagon-Like Peptide-1 Receptor Agonist.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Elderly individuals and those with osteoarthritis do not require dosage adjustments for the anti-inflammatory drug etodolac, as age and chronic use do not significantly alter its pharmacokinetics.

    Area of Science:

    • Pharmacology
    • Geriatric Medicine
    • Rheumatology

    Background:

    • The anti-inflammatory drug etodolac is commonly prescribed.
    • Understanding how age and chronic dosing affect etodolac pharmacokinetics is crucial for safe and effective geriatric use.

    Purpose of the Study:

    • To evaluate the impact of age and chronic dosing on the pharmacokinetic profile of etodolac.
    • To determine if dosage adjustments are necessary for elderly patients receiving etodolac therapy.

    Main Methods:

    • Pharmacokinetic parameters including peak concentration, time to peak, AUC0-24h, elimination half-life (t1/2), and free fraction were measured.
    • Comparisons were made between healthy young subjects, healthy elderly subjects, and elderly patients with osteoarthritis.
    • Single and chronic (7-day) dosing regimens were employed.

    Related Experiment Videos

    Main Results:

    • No significant differences in pharmacokinetic parameters were observed between young and elderly subjects (healthy or with osteoarthritis) after single or chronic dosing.
    • Chronic dosing led to expected increases in peak concentration and AUC0-24h across all groups, but did not alter free fraction, time to peak, or t1/2.
    • Etodolac did not accumulate significantly in elderly participants.

    Conclusions:

    • Age and chronic administration of etodolac do not significantly alter its pharmacokinetic profile.
    • Dosage adjustment of etodolac is not indicated for elderly patients.
    • This study supports the safe use of etodolac in geriatric populations without dose modification.